GEN Exclusives

More »

GEN News Highlights

More »
Jul 26, 2010

Immune Design Scores $32M in Series B Financing

  • Immune Design (IDC) secured $32 million in a Series B fundraising round. IDC is advancing a vaccine pipeline utilizing two proprietary technologies: glucopyranosyl lipid A (GLA), a synthetic toll-like receptor 4 (TLR-4) agonist, and DC-NILV, a delivery vector.

    GLA is an adjuvant reportedly being developed as a component in multiple in-house and partnered vaccine programs. It is a pure synthetic small molecule, straightforward to manufacture with excellent stability, and rationally designed to optimally activate human TLR-4 receptors, according to Immune Design. It induces Th1 CD4 helper cells and elicits humoral immunity, is active in multiple formulations, and is compatible with most antigens, the company adds. GLA was also shown to be safe and well-tolerated in human subjects in a Phase I clinical study in combination with Fluzone®. 

    DC-NILV is engineered to target human dendritic cells and express target antigens as well as immunomodulatory elements to elicit functional and broad-based immunity. It is initially being applied in cancer indications of significant unmet need.

    Today’s financing brings the total amount of equity capital raised since its inception in 2008 to $50 million. The round was led by ProQuest Investments and was joined by current investors The Column Group, Versant Ventures, and Alta Partners.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »